News

Article

ABEC Develops Single-Use Bioreactor for Emergent Manufacturing Facility

ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.

On Oct. 24, 2017, ABEC, a provider of engineering, equipment, and services to the biopharmaceutical manufacturing sector, announced that Emergent BioSolutions, a provider of contract manufacturing services, will equip its bulk manufacturing facility in Bayview, Baltimore, MD, with an ABEC 4,000-L custom single run (CSR) bioreactor.

The 4,000-L bioreactor will be designed specifically for Emergent’s process needs, operational requirements, and facility constraints, and will expand cell culture capacity at the Bayview site. The system can also deliver performance comparable to stainless steel systems, can be customized for different products, and is anticipated to improve cell culture productivity, process transfer, and scale-up, according to ABEC.

“ABEC’s CSR enables us to fully realize the benefits of single-use technology by improving flexibility while leveraging economies of scale,” said Scott Battist, Emergent BioSolutions’ vice president and general manager of the Bayview site, in a company press release.

Source: ABEC

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content